Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. NVDA
9. BLZE
10. NKE

Go back to Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere Therapeutics (TVTX) PT Raised to $18 at Barclays

September 30, 2024 6:13 AM EDT

Barclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $18.00 (from $14.00) while maintaining a Overweight rating.

The analyst comments "Forthcoming FSGS updates should provide steady set of catalysts de-risking regulatory path (adding $300mn+ to U.S. peak sales potential, and... More

Travere Therapeutics (TVTX) PT Lowered to $19 at Citi

September 27, 2024 7:23 AM EDT

Citi analyst Carly Kenselaar lowered the price target on Travere Therapeutics (NASDAQ: TVTX) to $19.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "The enrollment pause in the Ph3 HCU trial triggered by the pegtibatinase manufacturing scale-up not meeting required specs is obviously... More